Modulators of G-protein coupled receptors

US12281149B2 · kind B2 · utility

Assignee

• Carmot Therapeutics, Inc. · US

Inventors

• Daniel Erlanson · San Francisco, US
• Raymond V. Fucini · San Bruno, US
• Stig Hansen · Kensington, US
• Jeff Iwig · Berkeley, US
• Shyam Krishnan · Novato, US
• Enrique Moya · Berkeley, US
• Steven Sethofer · Emeryville, US

Key dates

• Filing date: May 13, 2022
• Grant date: Apr 22, 2025
• Expiry date: Oct 11, 2042

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K38/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt) that modulate (e.g., agonize or partially agonize or antagonize) glucagon-like peptide-1 receptor (“GLP-1R”) and/or the gastric inhibitory polypeptide receptor (“GIPR”). The chemical entities are useful, e.g., for treating a disease, disorder, or condition in which modulation (e.g., agonism, partial agonism or antagonism) of GLP-1R and/or GIPR activities is beneficial for the treatment or prevention of the underlying pathology and/or symptoms and/or progression of the disease, disorder, or condition. In some embodiments, modulation results in enhancement of (e.g., increases) existing levels (e.g., normal or below normal levels) of GLP-1R and/or GIPR activity (e.g., signaling). In some embodiments, the chemical entities described herein further modulate (e.g., attenuate, uncouple) β-arrestin signaling relative to what is observed with the native ligand. This disclosure also features compositions as well as other methods of using and making the said chemical entities.